2012•Clinical and Experimental HypertensionRequires access
Comparison of the Efficacy and Safety of Irbesartan and Olmesartan in Patients With Hypertension (EARTH Study)
Joji Morii, Shin‐ichiro Miura, Yuhei Shiga, Makoto Sugihara, Tadaaki Arimura, Hideto Sako, Bo Zhang, Yoshinari Uehara, Keijiro Saku
Open publisher page 9 citations
Abstract
Fifty-four patients were randomly divided into irbesartan and olmesartan groups. Blood pressure (BP) was significantly decreased in all patients at 12 weeks. In particular, BP in patients who initially received irbesartan showed significant reductions. The equality of variance of BP in the irbesartan group was significantly smaller than that in the olmesartan group at 12 weeks. Blood concentrations of adiponectin were significantly increased in the irbesartan group at 12 weeks. Log [pentraxin-3] in the irbesartan group were significantly decreased. In conclusion, the ability of irbesartan to reduce BP is comparable to that of olmesartan with equivalent safety.